Gilead to Buy Cancer Biotech Tubulis in $5B Deal

Gilead Sciences will acquire German biotech Tubulis for up to $5 billion, expanding its oncology pipeline with next-generation cancer therapies. The deal targets Tubulis’ proprietary antibody-drug conjugate (ADC) technology, a rapidly growing field in precision cancer treatment. Announced in April 2026, the acquisition reflects Gilead’s push to strengthen its portfolio amid fierce competition in oncology innovation. Tubulis, a private Munich-based firm, specializes in ADCs designed to deliver toxins directly to tumor cells, minimizing side effects. The transaction underscores Big Pharma’s aggressive investment in biotech startups to accelerate breakthrough therapies for unmet medical needs.